Trial · NCT01674621
Results by group185
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 185
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Percent Change From Baseline in Bone Mineral Density (BMD) of Lumbar Spine at 6 Months | Abaloparatide Transdermal (50 mcg) | 1.87 | Standard Deviation 2.87 | Percent change | |
| Percent Change From Baseline in Bone Mineral Density (BMD) of Lumbar Spine at 6 Months | Abaloparatide Transdermal (100 mcg) | 2.33 | Standard Deviation 2.96 | Percent change | |
| Percent Change From Baseline in Bone Mineral Density (BMD) of Lumbar Spine at 6 Months | Abaloparatide Transdermal (150 mcg) | 2.95 | Standard Deviation 3.13 | Percent change | |
| Percent Change From Baseline in Bone Mineral Density (BMD) of Lumbar Spine at 6 Months | Abaloparatide Injection (80 mcg) | 5.80 | Standard Deviation 4.21 | Percent change | |
| Percent Change From Baseline in Bone Mineral Density (BMD) of Lumbar Spine at 6 Months | Abaloparatide Transdermal Placebo (0 mcg) | 0.04 | Standard Deviation 2.47 | Percent change | |
| Percent Change From Baseline in BMD of Total Hip at 6 Months | Abaloparatide Transdermal (50 mcg) | 0.97 | Standard Deviation 1.95 | Percent change | |
| Percent Change From Baseline in BMD of Total Hip at 6 Months | Abaloparatide Transdermal (100 mcg) | 1.32 | Standard Deviation 1.96 | Percent change | |
| Percent Change From Baseline in BMD of Total Hip at 6 Months | Abaloparatide Transdermal (150 mcg) | 1.49 | Standard Deviation 1.73 | Percent change | |
| Percent Change From Baseline in BMD of Total Hip at 6 Months | Abaloparatide Injection (80 mcg) | 2.74 | Standard Deviation 3.05 | Percent change | |
| Percent Change From Baseline in BMD of Total Hip at 6 Months | Abaloparatide Transdermal Placebo (0 mcg) | -0.02 | Standard Deviation 2.39 | Percent change | |
| Percent Change From Baseline in BMD of Forearm at 6 Months | Abaloparatide Transdermal (50 mcg) | -0.24 | Standard Deviation 2.74 | Percent change | |
| Percent Change From Baseline in BMD of Forearm at 6 Months | Abaloparatide Transdermal (100 mcg) | -0.16 | Standard Deviation 3.71 | Percent change | |
| Percent Change From Baseline in BMD of Forearm at 6 Months | Abaloparatide Transdermal (150 mcg) | 0.84 | Standard Deviation 2.96 | Percent change | |
| Percent Change From Baseline in BMD of Forearm at 6 Months | Abaloparatide Injection (80 mcg) | 0.33 | Standard Deviation 3.41 | Percent change | |
| Percent Change From Baseline in BMD of Forearm at 6 Months | Abaloparatide Transdermal Placebo (0 mcg) | 0.05 | Standard Deviation 3.18 | Percent change | |
| Percent Change From Baseline in Serum Bone-Specific Alkaline Phosphatase (BSAP) at 6 Months | Abaloparatide Transdermal (50 mcg) | -4.84 | Standard Deviation 23.87 | Percent change | |
| Percent Change From Baseline in Serum Bone-Specific Alkaline Phosphatase (BSAP) at 6 Months | Abaloparatide Transdermal (100 mcg) | 5.22 | Standard Deviation 43.66 | Percent change | |
| Percent Change From Baseline in Serum Bone-Specific Alkaline Phosphatase (BSAP) at 6 Months | Abaloparatide Transdermal (150 mcg) | -5.52 | Standard Deviation 37.86 | Percent change | |
| Percent Change From Baseline in Serum Bone-Specific Alkaline Phosphatase (BSAP) at 6 Months | Abaloparatide Injection (80 mcg) | 17.30 | Standard Deviation 42.76 | Percent change | |
| Percent Change From Baseline in Serum Bone-Specific Alkaline Phosphatase (BSAP) at 6 Months | Abaloparatide Transdermal Placebo (0 mcg) | 10.23 | Standard Deviation 64.93 | Percent change |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT01674621/results